Can Newly Approved “Tissue Agnostic” Drugs Benefit Pediatric High-grade Glioma Patients? Recently, the U.S. Food and Drug Administration (FDA) granted accelerated approval* to the drug Rozlytrek (entrectinib, Genentech/Roche**) as a treatment for patients, 12 years or older, whose tumors have a specific genetic defect known as an “NTRK gene fusion.”*** This is now the second drug that the FDA has approved to treat patients with this […] September 16, 2019
Glossary Blog, June 2018: Pivotal Clinical Trial Pivotal Clinical Trial: A clinical trial or study intended to provide evidence for a new treatment approval by the United States Food & Drug Administration (FDA) This month we take a quick look at term that’s used in the field of biomedical research and drug development, that has both a figurative and an official technical/literal […] June 22, 2018
March 2018 Public Policy and Advocacy Updates For a number of years now, our Public Policy & Advocacy staff have put out monthly emails to those who’ve signed-up to be NBTS volunteer advocates, providing updates on the latest goings-on in the world of brain tumor public policy and issues related to legislation that impacts this community. As our advocacy program continues to […] March 30, 2018
Brain Tumor Research Highlights: July 2017 Cover photo courtesy of the National Cancer Institute (NCI) Over the years, NBTS has given more than $35 million to brain tumor research projects. We’re very proud of the impact this funding has made in advancing the neuro-oncology field closer to better treatments and ultimately a cure. And while NBTS is currently focused on driving our […] July 24, 2017
10 Key Takeaways from the 2016 National Brain Tumor Society Scientific Summit National Brain Tumor Society hosted its Annual Scientific Summit on Thursday, September 29, 2016, convening experts from some of the world’s top brain tumor research labs; leading brain tumor clinical centers; the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI); biopharmaceutical company researchers and executives; and patient advocates. Unlike most scientific-based […] October 17, 2016